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Low oxygen stimulates the 
immune system
JS Maltzman1 and VH Haase1
Changes in tissue oxygen levels trigger molecular signaling pathways 
that regulate cellular proliferation and differentiation in multiple 
cell types. The functional role of oxygen signaling in the immune 
system is not well understood. Rama and colleagues demonstrate that 
hypoxia induces dendritic-cell maturation; thus they provide a novel 
mechanistic link between hypoxia/ischemia and the activation of the 
immune system in the kidney.
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Tissue hypoxia as a result of cardiopulmo-
nary dysfunction or reduced oxygen-car-
rying capacity is a frequently encountered 
clinical problem, which in the worst-case 
scenario results in cellular death. Under 
physiological conditions, tissue oxygen 
levels provide important cues that are 
critical for normal embryonic develop-
ment, cellular diﬀerentiation, and stem-
cell maintenance. Like any other cell type, 
immune cells have to be able to respond 
and to adapt to a low-oxygen environ-
ment in order to generate the bioenergetic 
resources that allow them to survive and to 
continue to execute cell type-speciﬁc func-
tions under hypoxic conditions. Rama et 
al.1 (this issue) now report that hypoxia, 
similar to allogeneic stimulation, induced 
maturation of dendritic cells (DCs), 
which was associated with an increase 
in hypoxia-inducible factor-1α (HIF-
1α) protein levels and was attenuated by 
mammalian target of rapamycin (mTOR) 
inhibition. Although the underlying 
molecular mechanisms remain to be 
investigated, the authors’ data suggest that 
renal hypoxia induces an immune/inﬂam-
matory response that may promote and/or 
maintain renal injury (Figure 1).
Dendritic cells
DCs are an integral part of the immune 
system. The discovery and further char-
acterization of these cells over the past 
35 years led to Ralph Steinman receiv-
ing the Lasker Award in 2007. The term 
‘dendritic cell’ encompasses multiple cell 
types that share common characteristics. 
DCs are potent antigen-presenting cells, 
are derived from hematopoietic stem cell 
precursors in the bone marrow, and have 
also been shown to prime and amplify 
the innate immune response. They are 
distributed in a so-called ‘immature’ state 
in a variety of tissues, including skin, gas-
trointestinal tract, and kidney. Here they 
act as sentinels of immune surveillance, 
extending projections and engulfing 
antigens by endocytosis, phagocytosis, 
and pinocytosis. Peptides derived from 
exogenous antigens or cellular peptides 
are processed and presented by major 
histocompatibility complex class II and 
class I molecules, respectively. Activation 
of DCs leads to maturation with concomi-
tant migration to draining lymph nodes 
and upregulation of cell-surface proteins 
including several costimulatory receptors. 
Interaction of T lymphocytes with these 
mature DCs promotes T-cell activation, 
resulting in lymphocyte proliferation 
and diﬀerentiation into eﬀector cells that 
express signature cytokines such as inter-
leukin-4, interferon-γ, or interleukin-17.
Immature DCs found in the kidney 
(renal DCs, or rDCs) have traditionally 
been diﬃcult to isolate and study. How-
ever, it is clear that rDCs exist in several 
functional subsets based on cell-surface 
markers (reviewed by John and Nel-
son2). rDCs are present throughout the 
interstitium and as such are poised to 
survey this tissue for foreign antigen and 
respond to maturation signals from the 
innate immune system. Rama et al. have 
proposed short-term hypoxia as a novel 
maturation signal not only for mono-
cyte-derived DCs, but for rDCs as well.1 
This new mechanism for rDC maturation 
invites interesting speculation as to the role 
of rDCs in inducing the immune-medi-
ated response to renal hypoxia. The cellu-
lar and molecular mechanisms underlying 
the adaptive and innate immune response 
to ischemia–reperfusion are an active 
area of research in many laboratories. For 
example, CD4+ T cells are required in an 
ischemia–reperfusion injury (IRI) model 
of acute renal failure,3 and rDCs have 
recently been shown to be the predomi-
nant source of intrarenal tumor necrosis 
factor-α in early IRI,4 an observation that 
points to their pathophysiological impor-
tance in ischemic renal injury. Whether 
hypoxia-induced maturation of rDCs 
alone leads to their migration to regional 
lymph nodes, T-cell activation, and addi-
tional immune-mediated damage to the 
kidney requires further investigation.
Molecular oxygen sensing: Is there a role 
for HIF in dendritic-cell maturation?
Key factors in cellular adaptation to 
hypoxia are hypoxia-inducible factor-1 and 
factor-2 (HIF-1 and HIF-2), heterodimeric 
transcription factors that consist of an oxy-
gen-sensitive α-subunit, which under nor-
moxia is targeted for rapid degradation by 
the pVHL-E3-ubiquitin ligase, and a con-
stitutively expressed β-subunit (reviewed 
by Haase5). HIFs regulate the expression of 
gene products that control cellular energy 
metabolism and glucose transport, cel-
lular proliferation and differentiation, 
angiogenesis and erythropoiesis; classic 
HIF target genes include phosphoglycer-
ate kinase-1 (PGK), glucose transporter-1 
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(GLUT-1), vascular endothelial growth 
factor (VEGF), and erythropoietin (EPO) 
(reviewed by Haase5). Although HIF-α 
degradation is inhibited in cultured cells 
when oxygen levels fall below 5% O2, 
HIF-α proteins are usually not detectable 
in adult renal tissues, unless HIF-α prote-
olysis is inhibited pharmacologically, for 
example by cobalt chloride, or unless a 
signiﬁcant decrease in oxygen availability 
has occurred as a result of acute or chronic 
ischemia. In hypoxic kidneys HIF-1α has 
been detected in most cell types, whereas 
HIF-2α is expressed in cortical intersti-
tial, endothelial, and glomerular cells, as 
well as in macrophages, but is absent in 
renal tubular cells (reviewed by Haase5). 
Hypoxia through HIF-1 activation has 
been shown to modulate lymphocytic 
function and T-cell receptor signaling6,7 
and strongly impacts on inﬂammatory-cell 
recruitment and function.8,9 Along those 
lines, Rama et al. show that the hypoxic 
induction of DC maturation coincides 
with HIF-1α stabilization,1 suggesting 
that HIF-1 may play a role in this proc-
ess, pending more rigorous genetic and 
functional studies that directly examine 
whether HIF-1α is actually required for 
DC maturation under hypoxia. Thus, 
given these and other published observa-
tions, it is plausible that alterations of HIF 
signaling in inﬂammatory cells may play 
a fundamental role in immune-medi-
ated renal injury and inﬂammation. This 
potential injury-promoting function of 
HIF in immune cells is in contrast to its 
proposed cytoprotective role in ischemic 
renal disease (reviewed by Haase5), which 
has to be taken into account in the design 
of therapeutic strategies that aim at HIF-α 
stabilization to improve disease outcome.
Hypoxia, dendritic cells, and renal disease
Renal oxygen concentration can vary 
greatly; it is estimated to be about 5% O2 
(equivalent to ∼38 mm Hg) in the cortex 
and can be as low as 1% O2 (∼8 mm Hg) 
in the renal medulla. As a result of high 
renal oxygen demand and limited com-
pensatory mechanisms, renal hypoxia/
ischemia is a frequently encountered 
problem in clinical nephrology. Thus 
the observations by Rama et al.1 have 
broad implications for the pathogenesis 
of kidney diseases.
One of the most obvious settings in 
which hypoxia may play a role in immune-
mediated renal damage is the transplan-
tation setting. It is clear that IRI during 
transplantation contributes to the adaptive 
and innate immune response. Rama and 
colleagues1 oﬀer a new potential mecha-
nism whereby IRI may induce early acute 
allograft rejection. Here, hypoxia induced 
by removal of the organ and storage for 
transport could lead to rDC activation 
in addition to parenchymal damage. 
With the use of HIF-1α stabilization as a 
surrogate marker, substantial and wide-
spread hypoxia has been demonstrated 
in transplant biopsies immediately and 
even 10–14 days after renal engraftment.10 
Once transplanted into the recipient, 
donor rDCs would mature and migrate 
to regional lymph nodes, leading to direct 
allorecognition by the recipient’s T-cell 
repertoire. Direct allorecognition occurs 
when the recipient’s T cells respond to the 
donor’s major histocompatibility com-
plex molecules expressed on the donor’s 
antigen-presenting cells. T cells directed 
against foreign major histocompatibility 
complex are present at high frequency 
(approximately 1%–10%) compared with 
those directed at nominal peptide antigen 
(estimated to be <0.001% of the T-cell rep-
ertoire). Is hypoxia-induced rDC matu-
ration a major mechanism underlying 
the direct alloreactive response? Studies 
evaluating rDC migration and functional 
capacity following IRI will only begin to 
evaluate this potential mechanism.
Similarly to IRI in the transplant set-
ting, hypoxia-induced DC activation may 
contribute to the pathophysiology of acute 
injury of native kidneys, as CD4+ T cells 
are required in an IRI model of acute renal 
failure.3 Aside from immune-mediated 
glomerular diseases, another important 
scenario in which hypoxia activation of 
DCs could be relevant is chronic kidney 
disease (CKD). In CKD, hypoxia as a 
result of glomerulosclerosis and capillary 
rarefaction has long been thought to play 
an active role in disease progression, as it 
often precedes the development of ﬁbro-
sis.11 Although recent data demonstrated 
an active role for tubular-cell hypoxia and 
HIF-1 in this process,12 the presence of 
interstitial inﬂammatory inﬁltrates, a hall-
mark of CKD, illustrates the importance 
of inflammatory-cell responses in the 
progression of CKD. This notion is under-
scored by the observation that blockade of 
leukocyte recruitment substantially retards 
the development of chronic renal disease 
in rodents.13 The ﬁnding by Rama and col-
leagues that low oxygen induces DC matu-
ration1 therefore provokes further probing 
into the potential mechanistic links among 
hypoxia, the immune system, inﬂamma-
tion, and CKD progression.
Summary
Tissue oxygen levels play a fundamen-
tal role in the regulation of cellular 
proliferation and diﬀerentiation. Although 
Figure 1 | Schematic illustrating the role 
of hypoxia and hypoxia-inducible factor 
activation in dendritic-cell maturation. 
Rama et al. provide evidence that both hypoxia 
and the hypoxia mimetic desferrioxamine, 
a relatively nonspecific inhibitor of hypoxia-
inducible factor-α (HIF-α) degradation, induce 
maturation of dendritic cells (DCs);1 the latter 
observation suggests that activation of HIF 
signaling alone is sufficient to increase the 
percentage of differentiated DCs. Although 
the molecular mechanisms that underlie this 
process still need to be identified (dashed 
line), mammalian target of rapamycin (mTOR) 
inhibition decreased HIF-1α protein levels, 
as previously shown in cancer cells,14 and 











Kidney International (2008) 73          799
commentar y
there is mounting evidence that hypoxia 
modulates immune and inflammatory 
responses, the role of hypoxic signal-
ing in renal immune-mediated injury is 
largely unexplored. Rama and colleagues1 
propose that hypoxia is a key regulator of 
DC maturation in the kidney, suggest-
ing a novel mechanism by which oxygen 
regulates immune responses. Their work 
will stimulate future investigations into 
the role of molecular oxygen sensing in 
immune-cell maturation and function 
and has implications for acute and chronic 
renal injuries in the transplantation and 
non-transplantation settings.
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Hepatitis B in chronic kidney 
disease: Moving toward effective 
prevention
JK Unger1 and H Peters2
Control of hepatitis B virus (HBV) infection has been a continuous 
challenge in the management of patients with advanced kidney 
disease. HBV infections are still difficult to treat, so the main objective 
is disease prevention by timely immunization with hepatitis B surface 
antigen vaccines. In the general population, a simple two- or three-
standard-dose vaccination strategy has been proven to be highly 
successful. In contrast, an intensified and more tailored approach is 
evolving in patients with advanced renal failure.
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Infection and spread of hepatitis B virus 
(HBV) are a medical problem with glo-
bal dimension. More than 2 billion 
people are estimated to be infected 
with HBV worldwide, 360 million have 
chronic infection, and 600,000 die each 
year from HBV-related acute hepatitis, 
liver fibrosis, or hepatocellular car-
cinoma.1 HBV belongs to a family of 
hepadnavirus, consists of seven major 
genotypes (A to G), and is relatively 
small (approximately 45 nm in diam-
eter). Humans are the only natural host 
known, and virus transmission occurs 
primarily via direct blood or mucous 
membrane contact. The major envelope 
protein of HBV is the hepatitis B surface 
antigen (HBsAG). HBsAG was the ﬁrst 
identiﬁed blood marker for active HBV 
infection and was originally called ‘Aus-
tralia antigen.’1,2 HBsAG has become 
the main pathogen used for HBV vac-
cines. In the beginning, HBsAG vaccine 
was derived from plasma of infectious 
patients, but this has been replaced 
subsequently by recombinant vaccines 
produced in yeast.
Over the past 20 years, HBV vaccina-
tion has become one of the most eﬀective 
single medical interventions in the con-
trol of infectious disease. Rates of sero-
protection up to 95% have been achieved 
with a relatively simple two- or three-
standard-dose vaccination strategy.1,2 
Today’s HBV standard vaccine consists of 
20 µg HBsAG in conjunction with 0.5 mg 
aluminum salt as adjuvant. In the general 
population, seroprotection is deﬁned by 
an HBsAG antibody titer greater than 
10 mIU/ml. The HBV vaccine has been 
proven to be very safe, and there is no 
convincing evidence for any long-term 
undesirable sequel. As part of a global ini-
tiative, many countries have implemented 
